Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Office of AIDS Research (OAR)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

 Applicants should carefully note which ICOs participate in this announcement and refer to NIH Institute, Center, and Office Grants & Funding Profiles for ICO-specific missions, interest areas, priorities, and funding considerations.

Funding Opportunity Title

HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)

Activity Code

UM1 Research Project with Complex Structure Cooperative Agreement

Announcement Type

Reissue of RFA-AI-19-001

Related Notices

Funding Opportunity Number (FON)

RFA-AI-28-002

Companion Funding Opportunity

RFA-AI-28-001 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-003 , UM1 Research Project with Complex Structure Cooperative Agreement
RFA-AI-28-004 , UM1 Research Project with Complex Structure Cooperative Agreement

Number of Applications

See Part 2, Section III. 3. Additional Information on Eligibility.

Assistance Listing Number(s)

93.8RP, 93.HDR, 93.310, 93.242, 93.853, 93.AGR, 93.DA1, 93.HL6, 93.KRC, 93.DE1

Funding Opportunity Purpose

The purpose of the notice of funding opportunity (NOFO) is to support HIV/AIDS Clinical Trials Network Laboratory Centers (LCs). The LCs will provide a framework for laboratory leadership, structure and activities that contribute to the HIV/AIDS Clinical Trials Networks research agendas and execute the laboratory component of Network trials, in compliance with applicable regulatory standards.

Funding Opportunity Goal(s)

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability.

Key Dates

Posted Date

November 20, 2026

Open Date (Earliest Submission Date)

February 09, 2027
Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed Scientific Merit Review Advisory Council Review Earliest Start Date
March 09, 2027 March 09, 2027 Not Applicable July 2027 October 2027 December 2027

All applications are due by 5:00 PM local time of applicant organization. 

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

March 10, 2027

Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide, except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).

Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide, follow the program-specific instructions.

Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.
  3. Use Grants.gov Workspace to prepare and submit your application and eRA Commons to track your application.

Part 2. Full Text of Announcement

Section I. Notice of Funding Opportunity Description

Network Scope and Structure

The National Institute of Allergy and Infectious Diseases (NIAID) and its Institute, Center, and Office (ICO) partners will support four Clinical Trials Networks with unique research agendas that will conduct HIV/AIDS prevention, treatment and implementation science research improving uptake of evidence-based strategies across the lifespan:

  1. HIV/AIDS Adult Therapeutics Clinical Trials Network
  2. HIV/AIDS Maternal, Adolescent and Pediatric Clinical Trials Network
  3. HIV Prevention Clinical Trials Network
  4. Immune-Based Prevention Clinical Trials Network

Each HIV/AIDS Clinical Trials Network is composed collectively of the following clinical trials infrastructure designed to support a complex research agenda:

RFA-AI-28-001 - HIV/AIDS Clinical Trials Network Leadership and Operations Centers (LOCs)
RFA-AI-28-002 - HIV/AIDS Clinical Trials Network Laboratory Centers (LCs) – this notice of funding opportunity (NOFO)
RFA-AI-28-003 - HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (SDMCs)
RFA-AI-28-004 - HIV/AIDS Clinical Trials Network Clinical Trials Units (CTUs)

While the emphasis of each Network is on clinical trials, clinical research studies that are not NIH-defined clinical trials are also in scope when undertaken to support the program. For this NOFO, the term "clinical study" refers to both clinical trials and clinical research studies, and "clinical trial" is used to refer to a clinical trial only.

NIAID plans to fund one LC award for each Network. 

Each Clinical Trials Network will have an Executive Management Committee (EMC), established by the LOC, to coordinate the activities of the Network's LOC, LC and SDMC. 

NIAID is responsible for the oversight and safety of all study participants in clinical trials funded by NIAID, and will provide NIAID-convened Data and Safety Monitoring Boards (DSMBs) to monitor clinical trials. NIAID will provide additional support services for Network trials under an Investigational New Drug (IND) or Investigational Device Exemption (IDE).

The Division of AIDS (DAIDS) Clinical Laboratory Oversight Team (DCLOT) will contribute to, and oversee, the implementation of harmonized DAIDS clinical lab-related guidelines, standards, and requirements.  DCLOT will oversee DAIDS-funded contractual laboratory quality assurance resources to ensure that Network laboratories perform according to good clinical laboratory practices (GCLP).  

Laboratory Center Specific Responsibilities

The LC will oversee site-affiliated clinical as well as central specialized laboratories (e.g., immunology, pharmacology, virology), to monitor and ensure the reliability of protocol-specified laboratory testing. In addition, the aims of the LC include:

  • Support sample integrity from time of collection to final testing or storage; 
  • Use appropriate laboratory data capturing management and tracking systems; 
  • Implement an approach to select, determine readiness, and approve laboratories to participate in trials;
  • Promote the use of state-of-the-art laboratory assays in trials; and 
  • Serve as a mechanism to increase capacity and capabilities to meet NIAID future unanticipated needs related to emerging infectious diseases.

The LC is responsible for expert leadership and scientific oversight across all laboratory aspects of the Clinical Trials Network's (CTNs) research agenda, serving as a central force in advancing high-quality, coordinated scientific work. In close collaboration with protocol teams, it shapes the design and execution of laboratory components within studies, while also developing comprehensive guidance materials and delivering targeted training to ensure consistency and excellence. Its role extends to the evaluation, qualification, and ongoing oversight of participating laboratories–including clinical, central, and specialized facilities affiliated with study sites–ensuring adherence to NIAID, Clinical Laboratory Improvement Amendments (CLIA), Good Clinical Laboratory Practice (GCLP), and external quality assurance standards, as applicable.

A defining feature of the LC is its implementation of a flexible and cost-effective laboratory infrastructure. By integrating clinic-based, central, regional, and specialized laboratories, it enables rapid protocol activation and responsiveness to evolving research priorities. This structure supports the harmonization of laboratory processes across networks, promoting efficiency and comparability of data.

Working in coordination with protocol teams, the SDMC, NIAID quality assurance programs, and site partners, the LC ensures the integrity and reliability of specimen management systems, laboratory data platforms, regulatory compliance, and clinical quality management practices. It supports centralized testing for studies that span multiple CTNs, facilitates the storage and accessibility of specimens for future research, and drives the advancement of innovative and point-of-care assays suited for both clinical and implementation studies.

The LC also plays a critical role in enabling sponsor audits and strengthening research accountability. At the same time, it contributes to workforce development by fostering the training and mentorship of the next generation of HIV laboratory scientists, reinforcing long-term capacity and scientific leadership in the field.

The Research Agendas for the four Networks are as follows: 

1. HIV/AIDS Adult Therapeutics Clinical Trials Network – Responsible for supporting the advancement of therapeutics research toward the treatment and cure of adults living with HIV including implementation science and clinical research to improve the management of HIV-related co-morbidities, coinfections and aging. Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver, and expand the reach, scale-up, and sustainability of evidence-based treatment for HIV and HIV-associated diseases. 
  • Novel and Durable Interventions for HIV – strategies to achieve durable HIV suppression and improve treatment outcomes for adults living with HIV. 
  • Anti-retroviral (ART)-Free Remission (HIV Cure) - strategies to eradicate HIV or sustain virologic remission through immune-based interventions. 
  • Complications and Non-Infectious Comorbidities – strategies to improve the prevention, treatment and management of high-impact co-morbidities in PWH (e.g., neurocognitive, substance use disorders, cardiovascular diseases, lung diseases, diabetic and related metabolic and endocrine conditions, kidney, urologic and hematologic disease, oropharyngeal complications, aging associated conditions). 
  • Viral Hepatitis - novel treatment strategies for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. 
  • Tuberculosis - novel therapeutics and combination treatments for drug-sensitive and -resistant tuberculosis (TB). 

Additionally, this Network will be responsible for the clinical research infrastructure to support early-stage pilot trials of novel products and approaches; opportunities for intensive sampling of potential tissue reservoirs of HIV; and specialized laboratory capabilities for virologic and immunologic analyses.   

2. HIV/AIDS Maternal, Adolescent, and Pediatric Clinical Trials Network – Responsible for advancing research to generate the evidence base on novel, innovative therapies, interventions, methods, and strategic approaches for HIV and HIV-associated conditions in infants, children, adolescents, and pregnant/postpartum women, integrating implementation science across the product development lifecycle to speed their adoption and scale-up.  Key aspects to this research agenda include: 

  • Implementation Science - strategies to adapt, deliver and scale evidence-based interventions that optimize prevention for pregnant and breastfeeding women, strengthen maternal antiretroviral therapy (ART), tailor infant prophylaxis, and expand early and repeat HIV testing for breastfeeding infants and children. 
  • HIV Treatment and Prevention Innovations - antiretroviral drug and regimen innovations in appropriate long-acting (or pediatric-friendly oral) formulations for pediatric and maternal populations and infant postnatal prophylaxis. 
  • ART-Free Remission (HIV Cure) - strategies to achieve sustained virologic remission in pediatric populations, including strategies initiated in the immediate newborn period. 
  • Treatment and Prevention of Tuberculosis and Other HIV-associated Co-Infections - new drugs and regimens for treatment and prevention of drug-sensitive and resistant TB disease, both pulmonary and extrapulmonary (including central nervous system [CNS]); address treatment needs for congenital syphilis, viral hepatitis (B and C), and other important HIV-associated co-occurring infections. 
  • Brain and Mental Health and Other HIV-associated Comorbidities - Neuroprotective and neurotoxic effects of ART to preserve neurocognitive development and mental health in infants, children, and adolescents. Evaluate novel preventive and therapeutic approaches for other high-priority diseases and co-occurring conditions 

3. HIV Prevention Clinical Trials Network – Responsible for advancing products and strategies to meet the needs of populations vulnerable to HIV acquisition including adults, adolescents and pregnant women, through the integration of biomedical, socio-behavioral and structural prevention strategies, in partnership with implementing agencies and organizations. Key aspects to this research agenda include: 

  • Implementation Science – strategies to optimize deployment of and improve access to biomedical and socio-behavioral evidence-based interventions for HIV prevention. 
  • Integrated Prevention Strategies - integration of socio-behavioral research to optimize HIV prevention outcomes tailored to the population and context, to improve HIV treatment uptake and adherence, retention in care, and reduction of HIV risk. 
  • Novel Biomedical HIV Prevention and Delivery Systems - strategies and delivery methods that meet the needs of varied populations and help address the challenges of adherence. Multipurpose technologies (MPTs) – products designed to simultaneously protect against multiple sexual and reproductive health issues and potentially medications to treat or prevent other health conditions. 
  • Intersection of HIV and Other Sexually Transmitted Infections (STIs) - prevention and treatment strategies to address interaction between HIV and STIs. 

4. Immune-Based Prevention Trials Network – Responsible for the discovery and advancement of immune-based strategies to protect against HIV infection and associated infectious diseases, including TB and STIs, through Phase 1–3 clinical trials designed to answer key immunologic research questions to inform future candidate design, define correlates of protection, and identify safe and efficacious preventative regimens. Key aspects to this research agenda include: 

  • Antibody-Mediated Prevention for HIV - design and conduct Phase 1–3 trials of passive immunization strategies.     
  • Induced-Immunity for Prevention of HIV Acquisition - evaluate immunogens, immune modulators and adjuvants; and combinations of immunogens with antiretroviral drugs and other HIV prevention modalities.  Conduct rapid, iterative "discovery medicine" trials to evaluate novel immunogens and adjuvants. 
  • Analytical Treatment Interruption (ATI) Strategies - studies in PWH to evaluate viral control to inform HIV immune-based prevention approaches and immunotherapy development. 
  • Immune-based Prevention Strategies Against Other HIV-associated Infectious Diseases - evaluate interventions against other infectious diseases (e.g., TB and STIs) and how these diseases may influence the safety and effectiveness of HIV prevention approaches. 
  • Integration of Implementation and Behavioral Science Research - integration across all stages of immune-based product development and evaluation, assessing acceptability and mode of intervention. 
  • Determinants of Immune Function and Intervention Effectiveness - evaluate how the microbiome, diet and environmental exposures share or alter immune function and the effectiveness of prevention interventions.  

Other Research Areas: Each Network may have the opportunity to contribute to the research agenda for support of the development of strategies, interventions, and products for the rapid response against other/emerging infectious diseases (not listed above) of public health importance and to implement clinical trials in support of this agenda. The research agenda for those efforts will be developed post-award through cross-network, joint leadership efforts in conjunction with NIAID and other NIH staff.

Core and Protocol Funds

Funding to carry out the Network's research agenda falls into two categories:

Core Funds: initial fixed-base funding for infrastructure and salary support that is not protocol-specific. NIAID will provide core funds directly to the LOC, LC, SDMC and network-affiliated CTUs on an annual basis. 

Protocol Funds (PF): support to conduct protocols, including protocol-specific infrastructure or other requirements needed to conduct protocols at a clinical research site. PF varies annually, depending on costs of ongoing protocols. NIAID anticipates providing PF directly to the LOC, LC, SDMC and Network-affiliated CTUs on an annual basis. 

The LOC will estimate PF needs for the network (salary and non-salary PF) based on communications with the LC, SDMC, and CTUs/CRSs and submit an annual budget request to NIAID. 

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.

Application Types Allowed

New
Renewal - Renewals of RFA-AI-19-001

The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Clinical Trial?

Required: Only accepting applications that propose clinical trial(s).

Funds Available and Anticipated Number of Awards

NIAID and partner components intend to commit an estimated total of $29M to fund 4 awards in FY2028.

Award Budget

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Award Project Period

The project period must be 7 years. 

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions - Includes all types

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession

Other

  • Independent School Districts
  • Public Housing Authorities/Indian Housing Authorities
  • Native American Tribal Organizations (other than Federally recognized tribal governments)
  • Faith-based or Community-based Organizations
  • Regional Organizations

Foreign Organizations/Foreign Collaborations

Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.

Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.

Required Registrations

Applicant Organizations

Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications for additional information

  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM.
    • Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.
  • eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. Obtaining an eRA Commons account can take up to 2 weeks.

All PD(s)/PI(s) must be registered with ORCID. The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. 

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide.

2. Cost Sharing

This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.2 Definition of Terms.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice, or other notice from NIH Guide for Grants and Contracts). Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Page Limitations

All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions:

The Research Strategy must consist of the following sub-sections with the indicated page limits:

Sub-section A. Overview of the Proposed Laboratory Center, one required - 12 pages

Sub-section B. Scientific Leadership, Structure and Governance, one required - 6 pages

Sub-section C. Laboratory Science and Contribution to the Network Research Agenda, one required - 30 pages

Sub-section D. Laboratory Selection, Testing Capabilities and Quality Assurance, one required - 12 pages

Sub-section E. Specimen Management and Access, one required - 6 pages

Sub-section F. Network Data Management, one required - 6 pages

Sub-section G. Oversight of Laboratory Operations, one required - 6 pages

Sub-section H. Communication, Collaboration and Harmonization, one required - 6 pages

Sub-section I. Training and Mentoring, one required - 6 pages

Instructions for Application Submission

The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO.

SF424(R&R) Cover

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Project/Performance Site Locations

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Other Project Information

All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Senior/Key Person Profile

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Within the Common Forms for Biographical Sketch and NIH Biographical Sketch Supplement, highlight the following:

  • The relative experiences of the PD(s)/PI(s) in leading and managing a Laboratory Center for multi-center clinical trials in a complex structure.
  • The expertise of applicable key personnel in working with commercial off-the-shelf (COTS) clinical trial management systems including Electronic Data Capture (EDC) systems.

R&R Budget

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Only request Core Funds for the initial fixed-base funding, infrastructure and salary support that is not protocol-specific (e.g., administrative and management support, community education and engagement structures and activities, clinical quality management activities, record retention).

Do not request Protocol Funds (PF). PF includes protocol-specific personnel salary, participant recruitment and retention, protocol required tests and evaluations, participant reimbursement, community education and engagement structures and activities, and protocol specimen shipment and storage).

R&R Subaward Budget

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Cover Page Supplement

All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Research Plan

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

Specific Aims: Describe the scientific aims of the Laboratory Center (LC). Each application in response to this NOFO must address only the research agenda of one HIV/AIDS Clinical Trials Network and must state which one of the four HIV/AIDS Clinical Trials Networks the LC proposes to support.

Research Strategy: The Research Strategy section must consist of subsections A-I as designated below.

Sub-section A. Overview of the Proposed Laboratory Center 

  • Provide a high-level overview of the overall approach of the LC in support of the affiliated network's research priorities and ensuing scientific agenda, and describe the approach to accomplishing these goals, including a description of the LC structure/composition, and coordination and integration with the LOC, SDMC and CTUs/CRSs.

For renewal applications: Progress Report should be included in sub-section A.

Sub-section B. Scientific Leadership, Structure and Governance 

  • Describe in detail the LC structure, including plans for a staffing structure that capitalizes on the individual strengths of key personnel and other staff to achieve the goals of the LC (e.g., clinical pathologists, medical technologists, regulatory experts, laboratory science experts). Tables, diagrams, flow charts or organizational charts are strongly recommended. Provide an organization chart showing key personnel for leadership or decision-making positions in the LC.  Provide plans to ensure continuity/succession for Leadership roles.
  • Describe the approach to governance of the LC, including establishment of decision-making entities, their composition, roles, responsibility and authority.  Do not name or contact potential members who are not already key personnel in the application or provided Letters of Support.
  • Explain the processes to establish, review and execute competing scientific priorities and how to review and address changing needs, identify and coordinate changing resources, and evaluate and discontinue unproductive or unneeded activities.

Sub-section C. Laboratory Science and Contribution to the Network Research Agenda 

  • Describe the key scientific research priority areas of the appropriate network; highlight the laboratory research needed to support these scientific areas; provide a history of past similar support; and discuss knowledge gaps and future opportunities.
  • Describe the plans and approach to obtain in a timely manner access to laboratory science expertise as well as specialized, state-of-the-art laboratory testing capabilities (e.g., diagnostics, immunology, microbiology, pharmacology, virology etc.) to meet protocol testing needs.  Describe in detail the capabilities of identified specialized laboratories.
  • Describe the proposed process for coordination and integration with the network's scientific committees and protocol teams to contribute to sound protocol design (e.g., schedule of laboratory evaluations, choice of study endpoints) and inform on issues related to laboratory test feasibility, capability and capacity.
  • Describe the plans to provide sites and laboratories with protocol-associated guidance materials (e.g., laboratory manual), support tools (e.g., worksheets), and training suitable to different types of studies and locations of enrolled participants (e.g., applicable to implementation research).
  • Describe the plans and approaches to support the development, optimization, and evaluation of state-of-the art assays using diverse specimens for implementation in trial protocols and ancillary studies, while fostering intellectual and material collaborations among clinical and laboratory scientists to advance technology and enable clinically useful information and sound product advancement decisions.

Sub-section D. Laboratory Selection, Testing Capabilities, Quality Assurance and Oversight 

  • Describe the approach for implementing an efficient, flexible, and cost-effective laboratory structure that allows for rapid activation of study protocols and is responsive to changing needs. Include the process for identifying, qualifying, selecting and approving testing laboratories. Indicate the types of laboratories and their testing capabilities.
  • Describe the approach, considerations and processes, including coordination with NIAID-funded laboratory quality oversight resources to exercise oversight of trial-supporting laboratories to ensure the reliability and integrity of protocol-specified laboratory testing and standards of laboratory operations, allowing for approval of registrational studies by U.S. and non-U.S. regulatory entities, as well as the ability to inform on product development decisions.
  • Describe the approach for coordinating and harmonizing laboratory oversight activities when other Networks or NIH Institutes jointly participate in the conduct of the same protocol. 
  • Describe the approach to determining the required level of assay qualification or validation when assays are used as primary endpoints in: (1) non-Investigational New Drug (IND) trials, (2) IND trials where laboratory data will be used for regulatory submission and approval, and (3) IND trials (e.g., discovery medicine) where laboratory data are used for iterative product development.
  • Describe the approach and plan for quality management for LC activities needed to achieve and maintain compliance with ICHE6, 21 CFR part 11, Good Documentation Practice (GDP), and other standards (e.g., NIAID, Clinical Laboratory Improvement Amendments (CLIA), Good Laboratory Clinical Practice (GLCP), etc.)  in meeting regulatory compliance.

Sub-section E. Specimen Management and Access 

  • Describe how the LC will collaborate with protocol teams, CTU and/or CRS PD(s)/PI(s) and the SDMC to support reliable chain of custody and tracking of samples from point of acquisition to final testing or storage destination. Describe the tracking of Material Transfer Agreements (MTAs). Include a discussion on shipping challenges into and out of a country, if applicable, and how these may be addressed.
  • Describe how the LC will implement reliable and cost effective local and centralized short-and long-term storage of study samples.
  • Describe how the LC will collaborate with the network LOC and SDMC to promote timely access to stored specimens and associated data for future research by network investigators and by the broader scientific community.   

Sub-section F. Network Data Management 

  • Describe how the LC will coordinate with the SDMC to ensure the implementation of a validated and verifiable laboratory data management system that allows for the capture and export of laboratory test results according to regulatory standards, as well as ensure the timeliness of laboratory data export to the network SDMC.

Sub-section G. Oversight of Laboratory Operations 

  • Describe the approach, processes and tools for providing complete, effective and efficient oversight of all aspects of LC operations, including oversight of the specialty laboratories.

Sub-section H. Communication, Collaboration and Harmonization

  • Describe the plans to communicate and collaborate with other awarded LCs and other NIH-funded research groups to achieve efficient utilization of resources, harmonization in areas such as laboratory approval processing, assay costing, sample acquisition and test processes, as well as centralized specialized testing to ensure harmonization of such testing in support of studies put forward by the awarded LOCs.
  • Provide plans for data workflows and coordination with the SDMC, as appropriate, to support timely interim analyses and reporting, including controlled unblinding procedures that preserve trial integrity while enabling efficient product iteration.
  • Describe the plans to share data from completed studies.

Sub-section I. Training and Mentoring

  • Describe how the training needs of LC staff will be determined (e.g., new methodologies, technological advancements, regulatory requirements), implemented and evaluated. 
  • Provide the plans for promoting mentorship and involvement of the next generation of biomedical leaders in clinical laboratory science.

Letters of Support:

Provide appropriate letters of support necessary to demonstrate the support of collaborators who have a significant role in the application. Note that letters establishing intra-network and cross-network collaborations are not necessary.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide.

Other Plan(s): 

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

  • A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed.

Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide.

  • No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.

PHS Human Subjects and Clinical Trials Information

When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide, with the following additional instructions:

Other Requested Information

For Renewal applications with ongoing clinical studies, applicants must include a list of all ongoing clinical studies and/or the unique ClinicalTrials.gov identifiers. All information must be combined in one single attachment using the filename "Ongoing Clinical Studies". If appropriate, please indicate for each study the NIAID Division of AIDS (DAIDS).

If you answered "Yes" to the question "Are Human Subjects Involved?" on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the How to Apply - Application Guide must be followed with the following additional instructions:

Although applicants must be prepared for clinical trials, definite plans for such involvement will not be possible at time of application. A Study Record MUST not be completed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions:

All Applications must add and complete the Delayed Onset Study record and must check box "Anticipated Clinical Trial?".

Study Title: use "Multiple Delayed-Onset Studies"

Justification Attachment: Indicate each clinical study protocol developed during the project period will be subject to approval through a procedure that involves an initial concept submission and subsequent review by the HIV/AIDS Clinical Trials Network. If the concept receives approval, the next stage will be development of the protocol, which also must undergo review and approval prior to implementation through the HIV/AIDS Clinical Trials Network.

PHS Assignment Request Form

All instructions in the How to Apply - Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.

  • Awards issued under this notice of funding opportunity (NOFO) will be incrementally funded awards and may be issued for project periods of up to 7 years. Multi-year funded grants will not be allowed.
  • Grants awarded under this NOFO will not be provided the authority to automatically extend the final budget period one time to 12 months beyond the original project period end date shown in the Notice of Award. All extensions, including the first extension, will require prior approval. Please note a 7-year grant does not qualify for a no-cost extension.
  • Progress and financial reporting will be required and reviewed annually. All funds must be expended within the approved project period.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide. Paper applications will not be accepted.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization's profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply - Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed. 

Mandatory Disclosure

Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures, 2 CFR 200.113 and NIH Grants Policy Statement Section 4.1.36.

Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the HHS Office of Inspector Grant Self Disclosure Program at grantdisclosures@oig.hhs.gov. 

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria

Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

 

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?


 

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

Specific to this NOFO:

  • To what extent will the LC's activities be supported by a clear succession plan to ensure continuity of leadership?

 

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?


 

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Does the application adequately address the following, if applicable?

Study Design

Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, sex, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex and race/ethnicity?

Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

Data Management and Statistical Analysis

Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

Specific to this NOFO:

  • How well does the organizational structure and governance plan allow flexibility and enable the LC to meet its goals?
  • To what extent will the LC's activities substantially advance laboratory science and contribute to the network's research agenda?
  • To what extent are the procedures for managing study needs and selecting clinical site laboratories appropriate to support the Network research agenda?
  • How sufficient are plans for collaboration with other research groups?
  • How well do approaches for training and mentoring support LC staff and the next generation of biomedical leaders in clinical laboratory science?
  • How well does the approach and plan for quality management ensure regulatory compliance?

 

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?


Additional Review Criteria

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

 

Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?


 

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.


 

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for inclusion. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research. 


 

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following three points: (1) a complete description of all proposed procedures including the species, strains, ages, sex, and total numbers of animals to be used; (2) justifications that the species is appropriate for the proposed research and why the research goals cannot be accomplished using an alternative non-animal model; and (3) interventions including analgesia, anesthesia, sedation, palliative care, and humane endpoints that will be used to limit any unavoidable discomfort, distress, pain and injury in the conduct of scientifically valuable research. Methods of euthanasia and justification for selected methods, if NOT consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals, is also required but is found in a separate section of the application. For additional information on review of the Vertebrate Animals Section, please refer to the Worksheet for Review of the Vertebrate Animals Section.


 

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.


 

For Resubmissions (as applicable), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.


 

For Renewals (as applicable), the committee will consider the progress made in the last funding period.


 

For Revisions (as applicable), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.


Additional Review Considerations

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

 

Not Applicable.


 

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).


 

Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.


 

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.


 

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.


2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by CSR, in accordance with NIH peer review policies and practices, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Requests for reconsideration of initial peer review will not be accepted for applications submitted in response to this NOFO. 

Applications will be assigned on the basis of established referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. Funding decisions are based on the core tenets of a unified funding strategy, see ICO Funding Policies and Considerations. Applicants are strongly encouraged to also refer to the ICO-specific funding policies and considerations pages linked therein that build upon the agency-wide framework.

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.

Prior to making an award, NIH reviews an applicant's federal award history in SAM.gov to ensure sound business practices. An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov.  NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicant's integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 "Federal awarding agency review of risk posed by applicants."  This provision will apply to all NIH grants and cooperative agreements except fellowships.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement Section 2.4.4 Disposition of Applications.

Section VI. Award Administration Information

1. Award Notices

A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient's business official.

In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk.  For more information on the Notice of Award, please refer to the NIH Grants Policy Statement Section 5. The Notice of Award and NIH Grants & Funding website, see Award Process.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm

Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).

2. Administrative and National Policy Requirements

The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:

All federal statutes and regulations relevant to federal financial assistance, including those highlighted in NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.

By applying for or accepting federal funds from HHS, recipients certify compliance with all federal antidiscrimination laws and these requirements and that complying with those laws is a material condition of receiving federal funding streams. Recipients are responsible for ensuring subrecipients, contractors, and partners also comply.

Applicants and recipients are strongly encouraged to refer to the NIH Director's Statement of Priorities, entitled "Advancing NIH's Mission Through a Unified Strategy." 

Recipients are responsible for ensuring that their activities comply with all applicable federal regulations. Pursuant to 2 CFR 200.340, by accepting an NIH award, the recipient agrees that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates the program goals or agency priorities, in line with 2 CFR 200.340(a)(4).

Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.

Successful recipients under this NOFO agree that:

When recipients, subrecipients, or third-party entities have:

  • ongoing and consistent access to HHS owned or operated information or operational technology systems; and
  • receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.

Cybersecurity plans and procedures must at minimum include the following:

  • Develop cybersecurity plans and procedures, modeled after the NIST Cybersecurity framework, to protect HHS systems and data:
    • Identify:
      • Develop an inventory of all assets and accounts with access to HHS owned and operated information or operational technology systems or which obtain PII or PHI for the purposes of the award.
    • Protect:
      • Limit access to HHS owned and operated systems to only those in need of access to complete reward activities.
      • Require all staff to complete annual cybersecurity and privacy awareness training. Visit 405(d): Knowledge on Demand (hhs.gov) to obtain free trainings, if needed.
      • Enable multifactor authentication for all employees, subrecipients, and third-party entities to access HHS owned and operated information or operational technology systems.
      • Regularly backup sensitive data and test backups.
    • Detect:
      • Install anti-virus or anti-malware software on all devices, servers, and accounts used to connect to HHS owned and operated systems.
    • Respond:
      • Develop an incident response plan. See Incident-Response-Plan-Basics_508c.pdf (cisa.gov) to learn about developing incident response plans.
      • Have cybersecurity incident reporting procedures that ensure the relevant HHS awarding agencies are notified of a cybersecurity incident within 48 hours of discovery. A cybersecurity incident is defined as an unplanned interruption to a technology service or reduction in the quality of a technology service, or an occurrence that actually or potentially jeopardizes the confidentiality, integrity, or availability of an information system or the information the system processes, stores, or transmits.
    • Recover:
      • Investigate incidents and plug any security gaps identified. 

All activities proposed in your application and budget narrative must align with applicable law, including but not limited to statutes, executive orders, federal regulations and applicable judicial holdings.  Accordingly, discretionary awards shall not be used to fund, promote, encourage, subsidize, or facilitate; racial preferences or other forms of racial discrimination by the recipient, including activities where race or intentional proxies for race will be used as a selection criterion for employment or program participation; denial by the recipient of the sex binary in humans, or the belief that sex is a chosen or mutable characteristic; illegal immigration; or any other initiatives that compromise public safety.  If an application does not align, the application will not receive funding to the extent permitted by law and applicable court orders.

For applications involving substance abuse, the application must not support harm reduction. Please see Updated Funding Guidance for Recipients on Supplies and Services.

For applications involving funding Medication-Assisted Treatment (MAT) or medications for opioid use disorder (MOUD), this funding should be used to provide comprehensive treatment and recovery support services rather than medication-only models for opioid use disorder. Services should include medications, where clinically indicated, in conjunction with psychosocial and other treatment and recovery support services. Funding can also be used to support individualized tapering and discontinuation of medications when clinically indicated. Please see Updated Funding Guidance for Recipients on  MAT/MOUD.

As of October 1, 2025, HHS has adopted 2 CFR Part 200, with some modifications included in 2 CFR Part 300. These regulations replace those in 45 CFR Part 75. However, for NIH, under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs in 45 CFR 75 continue to apply to NIH awards. Consistent with the statute, NIH will not apply updated thresholds outlined within 2 CFR Part 200, at this time.

In administering programs under this and all funding announcements, NIH prioritizes: 

  • Research involving rigorous scientific methods, including for studies related to children and adolescents, where NIH is committed to approaches that reflect the highest standards of clinical care and child safety. 
  • Biological and physiological integrity: Recognizing the relevance of biological sex to health outcomes, NIH encourages applicants to account for sex-based health factors in program design, data collection, and service delivery where scientifically appropriate.
  • NIH will implement these priorities consistent with applicable laws, regulations, court orders, and all required administrative procedures. Applicants are encouraged to describe how their proposed programs align with these priorities in their project narratives. Funded activities must advance NIH's vision of protecting and improving the health and well-being of Americans. The particular focus is on those who are medically vulnerable, or live in areas with limited access to care. NIH's duty is to serve wisely, effectively, and with measurable results that justify every taxpayer dollar invested. 

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (HHS) grant administration regulations at 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and NIH as defined below.

The PD(s)/PI(s) will have the primary responsibility for:

  • In collaboration with the PD(s)/PI(s) of the Leadership and Operations Center (LOC) and Statistical and Data Management Center (SDMC):
    • Establishing policies and procedures for collaboration with Network elements and decision-making within the Laboratory Center (LC) to adapt to evolving research priorities over time.
    • Maintaining close communication and coordination including convening or participating in meetings and teleconferences with the LOC, SDMC, and affiliated Clinical Trials Units and Clinical Research Sites (CTU/CRSs). 
    • Verifying that studies are conducted in compliance with all applicable regulations including 21 CFR Part 11 and ICHE6R2 guidelines.
    • Managing involvement of industry or any other third party in studies supported by this award. Informing NIAID in the event that network recipient institutions enter into agreements that provide essential support to NIAID-sponsored clinical studies but are not actions as part of the Network awards. 
    • Establishing and adhering to policies and standard operating procedures, ensuring compliance with NIAID DAIDS clinical research policies. Providing policies and standard operating procedures upon request to NIAID within 90 days of issuance of an award.
    • Coordinating with NIAID DAIDS Clinical Research Products Management Center (CRPMC) contractor to facilitate availability and distribution of study products.  Working closely with Clinical Monitors or Regulatory Auditors to ensure proper completion of all actions and steps associated with on-site monitoring or auditing, including review of corrective and preventative action plans when problems are detected.
    • Ensuring that protocol suspensions are implemented immediately on notification and remains in effect until notified that NIAID has conducted any required audit and the audit report or remedial action is accepted by NIAID. The PD(s)/PI(s) will ensure that during the suspension period, no funds from this award are allowed for new accruals.
    • Participate in the Executive Management Committee. 
  • Maintaining primary responsibility for the overall planning, execution and review of all laboratory center activities including, but not limited to:
    • Aligning LC priorities with Network research priorities as coordinated by the LOC.
    • Delegating responsibilities to lead investigators of the individual laboratories comprising the LC.
    • Ensuring that laboratories meet applicable regulatory and quality standards and operate in accordance with DAIDS, local and national requirements.
    • Engaging, where appropriate, non-network expert investigators and laboratories and other NIH-supported resources when identifying, evaluating and implementing new tests, reagents and instruments for clinical studies.
    • Transferring technology and sharing scientific information between LC specialty laboratories and CTU/CRS-affiliated laboratories.
    • Ensuring the security of any personally identifiable information associated with test specimens, making specimens available for cross-trial and cross-network evaluation when required, and providing access to non-network investigators when appropriate.
  • Recipients will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

  • Facilitating coordination among the NIAID- and NIH-supported Clinical Trials Networks and research groups, clinical research support programs, and other U.S. Government agencies, promoting collaborations and facilitating information exchange.
  • Participating in scientific working groups and protocol teams, and as a voting member (sharing one vote) in scientific committees.
  • Identifying scientific gaps and organizing meetings to facilitate exchange of scientific and regulatory information, including during network meetings.
  • Coordinating contract resources that facilitate the provision of support services for clinical trials.
  • Participating in the presentation of research results, including publications.
  • Coordinating the negotiation of Clinical Trials Agreements (CTAs) and serve as the liaison with pharmaceutical companies (or other providers of investigational agents).
  • Notifying the recipient if NIAID will have the option to independently file an IND on investigational agents or an IDE on investigational devices evaluated in NIAID-supported clinical studies. NIAID will advise the investigators on the specific regulatory requirements for IND/IDE sponsorship. NIAID will provide current policies and procedures that govern the reporting of adverse events in NIAID-supported trials.
  • For studies in which NIAID is the IND/IDE sponsor, provide consultation on study treatment-related issues, including manufacturing, preparation, administration and availability of active dosage forms and placebo. When NIAID is not the regulatory sponsor, pharmaceutical support is provided on a case-by-case basis.
  • Ensuring the monitoring support contractor will visit the clinical research sites periodically to review selected protocols, provide training on general protocol conduct, review internal QA/QC plans, and audit pharmacies for clinical trials under IND/IDE. When NIAID is not the regulatory sponsor, clinical monitoring support is provided on a case-by-case basis.
  • Providing a variety of training activities to help the network ensure that consistent standards for protection of human subjects and clinical trial conduct and documentation are achieved across the NIAID-supported clinical trials networks. Training areas include, but are not limited to, regulatory requirements, good clinical practice (GCP), adverse event reporting, human subject protections, informed consent, and NIAID and NIH policies and procedures.
  • Ensuring review and approval for all protocols prior to participant enrollment. If a protocol is disapproved, NIAID will not provide investigational products or permit expenditure of NIH funds for the proposed investigation. When a protocol is not initiated within twelve months of NIAID approval, re-review and approval by NIAID will be required.
  • Participating in developing and approving safety monitoring plans for clinical trials, especially those involving more than minimal risk. Serving on protocol safety review teams to monitor safety and efficacy of the intervention(s) for ongoing studies, including overseeing Serious Adverse Events with NIAID Medical Officers responsible for their disposition. Reviewing safety team composition prior to study initiation and supporting DSMBs for select trials.
  • Oversee and make available DAIDS-funded contractual laboratory quality assurance resources to ensure that Network laboratories provide reliable test results performed in accordance with good clinical laboratory practices (GCLP) and for proficiency testing oversight and support for assay validations in the area of patient safety, diagnostics, clinical pharmacology, virology, immunology and microbiology.
  • Facilitating access to NIAID DAIDS Clinical Research Products Management Center (CRPMC) contractor to facilitate the availability and distribution of study products, on-site monitoring or auditing, and other pharmaceutical services. 
  • NIAID reserves the right to terminate or curtail a clinical study. 
  • Additionally, an agency program official or ICO program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.

Areas of Joint Responsibility include:

  • Implementing, monitoring, and updating the clinical research priorities for the network to ensure consistency and relevance.
  • Reviewing the network's research activities and goals on an agreed upon schedule (but no less than once every year).
  • When NIAID is not the regulatory sponsor, pharmaceutical support is provided on a case-by-case basis.
  • When NIAID is not the regulatory sponsor, clinical monitoring support is provided on a case-by-case basis.
  • On an ongoing basis, the LOC, LC, SDMC, and NIAID staff will jointly evaluate the progress of clinical trials, including enrollment benchmarks, site and laboratory quality, and data quality. NIAID and NIAID contractors may audit applicable sites, SDMC, and laboratories to assess GCP and data quality and integrity.
  • NIAID, in conjunction with the EMC will assess the performance of the LOC, LC, SDMC and CTUs/CRSs in an ongoing manner. The EMC will develop an evaluation plan with defined goals and measurable objectives linked to specific performance metrics and include remedial actions for sites failing to meet acceptable standards. Clinical research sites that fail to meet performance standards may be subject to withdrawal of funding.
  • Community Advisory Board (CAB) representatives will participate with NIAID and Network staff to evaluate and improve community engagement, strengthen communication within and across networks, and identify training and support needs for both local and Network advisory boards.
  • NIAID may seek evaluation, advice and recommendation concerning ongoing and planned research activities of the network from external advisors. Advisors will not include key personnel or collaborators of the key personnel of any of the recipients. Network investigators will participate in these evaluations and will provide written materials and oral presentations regarding the status of ongoing research activities, future (including proposed new research activities/investigators), and plans to curtail, discontinue and/or modify current research activities.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between recipients and NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened: a designee of the recipient, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and HHS regulation 45 CFR Part 16.

3. Data Management and Sharing

A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page. The DMS Plan must address the elements in the structured format. Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed. 

4. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement Section 8.4.1 Reporting. To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see Post-Award Monitoring and Reporting.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement Section 8.6 Closeout. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk - Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues.

Grants.gov Support Center - Questions regarding Grants.gov registration and services (e.g., Workspace, subscriptions).

Scientific/Research Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: sciops@niaid.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: ctrisgrants@nih.gov
Subject: RFA-AI-28-002

National Institute on Aging (NIA)
Email: NIA-NOFO-Scientific@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichd_mpidb_nofos@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: NIDCR-Program@nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Division of Diabetes, Endocrinology and Metabolic Diseases
Email: NIDDK_DEM@nih.gov 
Division of Digestive Diseases and Nutrition
Email: NIDDK_DDN@nih.gov 
Division of Kidney, Urologic, and Hematologic Diseases
Email: NIDDK_KUH@nih.gov 

National Institute on Drug Abuse (NIDA)
Email: NIDAHIVProgram@mail.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMH.DAR.inquiries@nih.gov

National Institute of Neurological Disorders and Stroke (NINDS)
Email: NINDSNeuroHIV@nih.gov 

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

National Institute of Allergy and Infectious Diseases (NIAID) 
Email: niaidfinancial-grantscontact@mail.nih.gov

Office of AIDS Research (OAR)
Email: OARinfo@nih.gov

National Heart, Lung and Blood Institute (NHLBI)
Email: NHLBIOGMInbox@nhlbi.nih.gov
Subject: RFA-AI-28-002

National Institute on Aging (NIA)
Email: NIA-NOFO-Grants@nih.gov
Please include the NOFO number in the subject line when emailing.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Email: nichdgrantsmanagement@mail.nih.gov

National Institute of Dental and Craniofacial Research (NIDCR)
Email: deeranotifications@nidcr.nih.gov

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Email: NIDDKGMBManagementTeam@niddk.nih.gov 

National Institute on Drug Abuse (NIDA)
Email: nidagmbemail@nida.nih.gov

National Institute of Mental Health (NIMH)
Email: NIMHNOFOGrantsManagement@mail.nih.gov   

National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.